Evidence map›Paper›PMID 36644506›Full record

ArticleAtherosclerosis plus2021

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile.

Maria Giovanna Lupo, Diletta Arcidiacono, Alice Zaramella, Fabio Fimiani, Paolo Calabrò, Angelo Baldassare Cefalù, Maurizio Averna, Laura D'Erasmo, Marcello Arca, Sara De Martin and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Atherosclerosis plus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Lipoprotein a - Lp(a).Indian heart journal · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Maria Giovanna LupoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padua, Italy.
Diletta ArcidiaconoDigestive Endoscopy Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Alice ZaramellaDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Fabio FimianiA.O.R.N. Sant'Anna e San Sebastiano, Caserta Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Paolo CalabròA.O.R.N. Sant'Anna e San Sebastiano, Caserta Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Angelo Baldassare CefalùDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Maurizio AvernaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Laura D'ErasmoDepartment of Translational and Precision Medicine, Sapienza, University of Rome, Rome, Italy.
Marcello ArcaDepartment of Translational and Precision Medicine, Sapienza, University of Rome, Rome, Italy.
Sara De MartinDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padua, Italy.
Alberto ZambonDepartment of Medicine, University of Padova, Padua, Italy.
Nicola FerriDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padua, Italy.
University of Padua · ITSapienza University of Rome · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Palermo · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

Indexed as

Familial hypercholesterolemiaLomitapidelp(a)pcsk9

Identifiers

PMID36644506
PMCPMC9833247
OpenAlexW3173189774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.